Immunodeficiency Stocks List

Immunodeficiency Stocks Recent News

Date Stock Title
Oct 31 BMY Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
Oct 31 BMY A promising schizophrenia drug showed mixed results. What does that mean for patients?
Oct 31 BMY Bristol-Myers Squibb Company (BMY) Q3 2024 Earnings Call Transcript
Oct 31 BMY Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript
Oct 31 BMY Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View
Oct 31 BMY Bristol Myers Stock Rises. The Drugmaker Hiked Guidance After Sales Beat.
Oct 31 BMY Bristol Myers Screams To A Year-High After Walloping Profit Expectations
Oct 31 BMY Bristol Myers Squibb stock rises, Merck moves lower. Here's why.
Oct 31 BMY Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit
Oct 31 BMY Compared to Estimates, Bristol Myers (BMY) Q3 Earnings: A Look at Key Metrics
Oct 31 HOOK HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
Oct 31 GILD Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Oct 31 CODX Is Co-Diagnostics (NASDAQ:CODX) In A Good Position To Deliver On Growth Plans?
Oct 31 BMY Bristol-Myers Squibb in charts: Q3 revenue from Eliquis, Opdivo, Yervoy rises, Sprycel falls
Oct 31 BMY Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates
Oct 31 BMY Bristol-Myers raises outlook ahead of consensus after Q3 beat
Oct 31 BMY Bristol-Myers hikes annual earnings guidance as Q3 exceeds expectations; shares up
Oct 31 BMY Bristol Myers earnings beat expectations, driven by sales of older drugs
Oct 31 BMY Bristol Myers: Q3 Earnings Snapshot
Oct 31 BMY Bristol-Myers Squibb Company  Non-GAAP EPS of $1.80 beats by $0.30, revenue of $11.89B beats by $640M
Immunodeficiency

Immunodeficiency, also known as immunocompromisation, is a state in which the immune system's ability to fight infectious diseases and cancer is compromised or entirely absent. Most cases are acquired ("secondary") due to extrinsic factors that affect the patient's immune system. Examples of these extrinsic factors include HIV infection and environmental factors, such as nutrition.
Immunocompromisation may also be due to genetic diseases/flaws. An example here is SCID.
In clinical settings, immunosuppression by some drugs, such as steroids, can either be an adverse effect or the intended purpose of the treatment. Examples of such use is in organ transplant surgery as an anti-rejection measure and in patients suffering from an overactive immune system, as in autoimmune diseases. Some people are born with intrinsic defects in their immune system, or primary immunodeficiency.A person who has an immunodeficiency of any kind is said to be immunocompromised. An immunocompromised individual may particularly be vulnerable to opportunistic infections, in addition to normal infections that could affect anyone. It also decreases cancer immunosurveillance, in which the immune system scans the body's cells and kills neoplastic ones.

Browse All Tags